Recent publications · Crossref
5 total works indexed
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
· 2015 · cited 7,001x
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
· 2018 · cited 3,064x
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
· 2019 · cited 2,836x
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
· 2019 · cited 2,653x
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
· 2017 · cited 2,081x
via Crossref · CC0